The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19
The review highlights the problem of finding new effective treatment strategies for COVID-19. Tumor necrosis factor α (TNF-α) is considered as a therapeutic target. The theoretical basis for the successful use of TNF-α inhibitors (ITNFα) for the treatment of COVID-19 is presented, as well as data on...
Main Authors: | E. S. Aronova, B. S. Belov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-04-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1128 |
Similar Items
-
Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis
by: Jiwon Hwang, et al. -
Efficacy and Safety of Tumour Necrosis Factor-α Antagonists for Folliculitis Decalvans: A Retrospective Case-series Pilot Study
by: Aurore Dupont, et al.
Published: (2023-03-01) -
A retrospective, observational study to examine the effect of early tumor necrosis factor inhibitor use on rates of surgery for Crohn’s disease in Japan
by: Tetsuya Ishida
Published: (2025-02-01) -
De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review
by: Marleen Bouhuys, et al.
Published: (2022-04-01) -
Janus kinase inhibitors in immunoinflammatory rheumatic diseases
by: Evgeny L. Nasonov
Published: (2022-06-01)